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Abstract
Mutations in multiple oncogenes including KRAS, CTNNB1, PIK3CA and FGFR2 have been identified in endometrial cancer.
The aim of this study was to provide insight into the clinicopathological features associated with patterns of mutation in
these genes, a necessary step in planning targeted therapies for endometrial cancer. 466 endometrioid endometrial tumors
were tested for mutations in FGFR2, KRAS, CTNNB1, and PIK3CA. The relationships between mutation status, tumor
microsatellite instability (MSI) and clinicopathological features including overall survival (OS) and disease-free survival (DFS)
were evaluated using Kaplan-Meier survival analysis and Cox proportional hazard models. Mutations were identified in
FGFR2 (48/466); KRAS (87/464); CTNNB1 (88/454) and PIK3CA (104/464). KRAS and FGFR2 mutations were significantly more
common, and CTNNB1 mutations less common, in MSI positive tumors. KRAS and FGFR2 occurred in a near mutually
exclusive pattern (p=0.05) and, surprisingly, mutations in KRAS and CTNNB1 also occurred in a near mutually exclusive
pattern (p=0.0002). Multivariate analysis revealed that mutation in KRAS and FGFR2 showed a trend (p=0.06) towards
longer and shorter DFS, respectively. In the 386 patients with early stage disease (stage I and II), FGFR2 mutation was
significantly associated with shorter DFS (HR=3.24; 95% confidence interval, CI, 1.35–7.77; p=0.008) and OS (HR=2.00; 95%
CI 1.09–3.65; p=0.025) and KRAS was associated with longer DFS (HR=0.23; 95% CI 0.05–0.97; p=0.045). In conclusion,
although KRAS and FGFR2 mutations share similar activation of the MAPK pathway, our data suggest very different roles in
tumor biology. This has implications for the implementation of anti-FGFR or anti-MEK biologic therapies.
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Introduction
Endometrial cancer comprises about 4% of cancer in women
globally, with higher incidence in developed countries. The
American Cancer Society estimates endometrial cancer will be
the fourth most common cancer diagnosed and the eighth leading
cause of cancer deaths in women in 2010 [1]. Approximately 80%
of women are diagnosed with early stage cancers, clinically
confined to the uterus. Early diagnosis of endometrial cancer
contributes to the relatively good overall long-term survival.
However, for women who present with late stage disease or who
suffer recurrences, outcomes are poor. The five-year survival for
women with recurrent, progressive or metastatic endometrial
cancer is estimated as only 13% [2].
Considerable effort has gone into developing systems to more
effectively identify patients with endometrioid endometrial cancer
that carry an elevated risk of recurrence so they can be targeted for
adjuvant therapies (radiation, hormonal therapy, chemotherapy or
combination therapies). Those patients that present with extra-
uterine disease (stage III/IV) carry a high risk of recurrence and
progression. The majority of patients (,80%), however, present
with tumors clinically confined to the uterus (stage I/II). In these
early stage patients, multiple studies have shown that the risk of
recurrence is associated with tumor grade, depth of myometrial
invasion, occult extension into the cervix and tumor cell invasion
of lymphatic vessels (lymphovascular space invasion: LVSI), where
high grade is the most widely accepted adverse prognostic marker
[2,3]. The identification of molecular prognostic markers that
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clinical need.
Since 1988, the International Federation of Gynecology and
Obstetrics (FIGO) has recommended full systematic pelvic and
para-aortic lymphadectomy as part of staging for endometrial
cancer. A new 2009 FIGO staging system has recently been
implemented where tumors with no evidence of myometrial
invasion are combined with tumors that show invasion to less than
50% of the myometrium and grouped into stage 1A [4]. There is
considerable controversy in the literature as to the benefit of
lymphadectomy (measured as disease-free and overall survival) in
management of endometrial cancer patients. Some of the
conflicting results may reflect difference in study designs and
analysis methods. Some studies have reported improved survival in
those patients with early stage cancers but only in those with high
histologic grade [5]. More recently, there have been several large
multicenter clinical trials that have indicated systematic pelvic
lymphadectomy does not improve disease free or overall survival
[6,7]. Thus, for many patients in the United States and most
patients worldwide, lymph nodes are not removed and patients are
treated based on uterine risk factors alone. The development of
prognostic markers that could be used for risk stratification and to
inform subsequent treatment options is clearly needed for early
stage patients.
FGFR2 has been shown to be activated in a number of cancers
due to gene amplification [8,9,10] and point mutation [11,12,13].
Our group previously reported somatic activating fibroblast growth
factor receptor 2 (FGFR2) mutations in 18/115 (16%) endometrioid
endometrial cancers [14]. Two independent studies subsequently
reported a mutation frequency of 10% [11,15]. In our initial
analysis of 115 cases there was over-representation of higher stage
cancers that subsequently recurred and of tumors that had lost
DNA mismatch repair (MSI-positive cancers). The objective of the
current study was to determine the prevalence of FGFR2,
CTNNB1, KRAS and PIK3CA mutation in a large, unselected
cohort of endometrioid endometrial cancers and to determine the
relationship between mutation status and clinicopathologic
variables including outcome. Mutations in PTEN were not
included in this analysis due to the increased cost associated with
sequencing all 9 exons of this tumor suppressor gene. In addition,
the high prevalence of PTEN aberration (70%) argued against a
possible association with poor prognosis in this tumor type.
Materials and Methods
Ethics statement
All research subjects provided written consent to ongoing
protocols 91-507 and 93-0828, approved by the Washington
University’s Human Research Protection Office continuing
Review Committee. The work performed at TGen was deter-
mined to be exempt from IRB approval following review and
receipt of a Verification of Protections for Human research
subjects form signed by Dr Goodfellow and a copy of the blank
consent form.
Study participants and clinical data
Tumor specimens were prospectively collected at the time of
hysterectomy (1991–2006) for patients treated by the Division of
Gynecologic Oncology at Washington University School of
Medicine/Barnes–Jewish Hospital. Surgical staging and tumor
grade was assigned on the basis of FIGO 1988. Patients who had
received preoperative radiation or chemotherapy were excluded
from analysis. The prospectively collected clinical and pathologic
information was stored in a computerized database. Following
their initial treatment, these patients were routinely followed at 3-
month intervals for the first 2 years and then at 6-month intervals
for at least 3 years. Disease surveillance included physical
examination and periodic pap smears. Diagnostic imaging and
directed biopsies were performed as clinically indicated. Histolog-
ical confirmation of all recurrences was performed. Follow-up data
were abstracted from clinic charts, hospital records, and the
Siteman Cancer Center/Barnes-Jewish Hospital’s cancer registry.
Patients for whom follow-up data were unavailable or who died
perioperatively (within 30 days of hysterectomy) were excluded
from the analyses. The study population comprised 466 patients
with endometrioid endometrial cancer, 386 of which had disease
confined to the uterus (stage I or II).
Tissue processing, FGFR2 mutation analysis
Tissue specimens and blood were obtained at the time of
surgery, snap frozen, and stored at 270uC. Tumors were
evaluated to select tissues with .66% neoplastic cellularity for
DNA preparations. DNA was isolated using proteinase K and
phenol extraction or the DNeasy Tissue Kit (Qiagen Inc,
Valencia, CA). DNA was extracted from peripheral blood
leukocytes or, when blood was not available, from uninvolved
myometrium, as previously described [16,17].
Exons 7, 8, 10, 13 and 15 of FGFR2, exon 2 of KRAS, exon 3 of
CTNNB1, and exons 9 and 20 of PIK3CA were tested for
mutations by direct sequencing. PCR primers and conditions are
available upon request [18,19]. Sequences were analyzed using
Sequencher (Gene Codes, Ann Arbor, MI). Mutation analysis was
performed on blinded samples. All potential mutations were
confirmed with repeat amplification and sequencing of the exon of
interest. Matched normal DNA was analyzed to confirm the
mutation arose somatically for all mutations in FGFR2 and KRAS
and CTNNB1. For PIK3CA, rare and novel mutations were
confirmed to have arisen somatically and common tumor-
associated mutations were confirmed in the majority of samples.
Microsatellite instability (MSI) testing
MSI analysis is routinely performed for all tumors. The MSI
status and methods used for the majority of the cases reported here
have been previously described [20].
Statistical analysis
The relationship between gene mutation status and covariates
was assessed using Fisher’s exact test or Student’s t-test as
appropriate. Overall survival (OS) was defined as the time from
date of surgery to death due to any cause. Survivors were censored
at the date of last contact. Disease free survival (DFS) was defined
as the time from surgery to recurrence or progression. Patients
were excluded if they had died within 30 days of surgery. The
Kaplan-Meier product limit method was used to estimate OS and
DFS. Univariate and multivariate Cox proportional hazard
models were fitted to assess the effects of the covariates on OS
and DFS, and the proportional hazard assumptions were checked
using scaled Schoenfeld residuals [21]. Clinically accepted poor
prognostic covariates that were significant on univariate analysis
were included in the model including stage, grade and age. In the
analysis of DFS, Gray’s competing risk methods were also used to
account for the potential competing effect of death [22]. All
analyses were two-sided and significance was set at a p-value of
0.05. Statistical analyses were performed using SAS (SAS
Institutes, Cary, NC), as well as the cmprsk R (http://biowww.
dfci.harvard.edu/,gray) statistical packages for competing risk
analysis.
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The mean age at diagnosis for the 466 cases analyzed was 63.7
years with a mean follow-up time of 70.2 months (0.7–176). The
majority of patients presented with early-stage disease (386 or 83%
stage I or II) (Table 1). Mutation analysis was successful for the
four genes of interest as follows: FGFR2 (466 tumors, 100%); KRAS
and PIK3CA (464 tumors, 99%); and CTNNB1 (454 tumors, 97%).
Mutation data for all four genes was obtained for 453 cases (97%).
Prevalence and spectrum of FGFR2 mutations
We identified FGFR2 mutations in 48/466 (10.3%) tumors
(Table S1), including 115 previously investigated cases [18]. One
FGFR2 sequence alteration we originally reported as a frameshift
(c.2287-88delCT) was excluded from analyses because of uncer-
tainty as to whether the sequence change was functionally
significant. The most common mutations were S252W (n=18;
37%) and N550K (n=12, 25%). All together, 7 mutations
affecting 6 codons (S252W, P253R, Y376C, C383R, N550K,
N550H and K660E) accounted for 90% of the mutations
identified (Figure 1). We identified two additional novel mutations
in the transmembrane domain not previously described (V396D
and L398M), both of which we presume to be pathogenic. The
valine at FGFR2 codon 396 is highly conserved across species and
between FGFR1-FGFR3 family members. Furthermore, similar
substitutions in the transmembrane region of FGFR3 have been
shown to be activating. Replacement of a hydrophobic residue
with a glutamic acid in FGFR3 (A391E) has been identified both
in the germline of patients with Crouzon syndrome [23] and as a
somatic mutation in bladder cancer [24]. Functional studies have
indicated the A391E mutation stabilizes the active dimer via
hydrogen bonds [25]. We also hypothesize that by analogy the
L398M mutation (a conservative substitution resulting in the
introduction of a larger hydrophobic residue) is similarly
pathogenic. This mutation may result in a structural change
leading to a more active conformation, or may promote receptor
activation independent of structural changes e.g. altered protein
turnover as has been shown for the G380R mutation in FGFR3
[26]. Functional studies will be required to conclusively confirm
these mutations result in receptor activation.
Prevalence and spectrum of KRAS mutations
We identified mutations at codons 12 and 13 in KRAS in 87/464
(19%) samples, including 115 previously investigated cases [19].
The two most common mutations were G12D (33%) and G12V
Table 1. Patient Demographics and Clinicopathologic Characteristics.
Clinicopathologic Category Subcategory
Entire Cohort of 466 Endometrioid
Endometrial Tumors
Cohort of 386 Low Stage
Endometrioid Endometrial Tumors
Mean Age at Diagnosis (SD) 63.7 (11.7) 63.5 (11.6)
Follow-up Time (Mean) 70.2 months (0.7–176) 75.4 months (1.4–176)
Race Caucasian/Asian 411 (88%) 338 (88%)
African American 55 (12%) 48 (12%)
FIGO Stage 1A 85 (18%) 85 (22%)
1B 192 (41%) 192 (50%)
1C 71 (15%) 71 (18%)
IIA 18 (4%) 18 (5%)
IIB 20 (4%) 20 (5%)
III 62 (13%) -
IV 18 (4%) -
Grade 1 249 (53%) 225 (58%)
2 152 (33%) 122 (32%)
3 65 (14%) 39 (10%)
Recurrence No 399 (86%) 353 (91%)
Yes 67 (14%) 33 (8.5%)
Vital Status Alive 318 (68%) 283 (73%)
Dead 148 (32%) 103 (27%)
MSI No 308 (66%) 257 (67%)
Yes 158 (34%) 129 (33%)
FGFR2 Mutation No 418 (90%) 347 (90%)
Yes 48 (10%) 39 (10%)
KRAS Mutation No 377 (81%) 311 (81%)
Yes 87 (19%) 73 (19%)
CTNNB1 Mutation No 366 (81%) 298 (79%)
Yes 88 (19%) 78 (21%)
PIK3CA Mutation No 360 (78%) 291 (76%)
Yes 104 (22) 93 (24%)
doi:10.1371/journal.pone.0030801.t001
FGFR2 Mutations and Endometrial Cancer Prognosis
PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e30801(29%), which is similar to the frequencies observed in the Catalog
of Somatic Mutations in Cancer (COSMIC) (39% and 22%,
respectively) in endometrial tumors. All mutations observed had
been reported previously (Table S2).
Prevalence and spectrum of PIK3CA mutations
We identified 29 different mutations in exon 9 and 20 of
PIK3CA in a total of 104/464 (22%) cases (Table S3). The majority
of these (65/104, 63%) occurred in the kinase domain encoded by
exon 20 with the two most common mutations being E545K and
H1047R. We identified 2 novel mutations in exon 20, L1006F and
Q1014H. These non-conservative missense changes occurred in
the highly conserved C-terminal portion of the protein. In silico
predictions using SIFT indicate L1006F would be tolerated but
Q1014H would not, whereas PolyPhen classifies L1006F as
possibly damaging and Q1014H as benign. Although, in the
absence of functional studies, the caveat exists that these mutations
may indeed be passenger mutations and impart no increased
‘‘fitness’’ to the tumor, they were included in the current statistical
analysis as pathogenic given that the functional validation of many
more common mutations as oncogenic has not been reported.
Prevalence and spectrum of CTNNB1 mutations
We identified 21 different mutations in CTNNB1 in 88/454
(19%) endometrioid tumors (Table S4). The three most common
mutations occurred at D32Y (13%), S33C (11%), S37F (17%). All
mutations had been reported previously.
Prevalence of microsatellite instability and association
with mutations
158/466 (34%) of tumors were MSI positive. Mutations in
KRAS were significantly more common in MSI positive tumors
(42/158; 28%) compared to microsatellite stable (MSS) tumors
(45/306; 14%) (p=0.003, Fisher’s exact test). Similarly, mutations
in FGFR2, were significantly more common in MSI positive
tumors (24/158; 15%) compared to MSS tumors (24/308; 8%)
(p=0.016). In contrast, mutations in CTNNB1 were significantly
less common in MSI positive tumors (17/152; 11%) compared to
MSS tumors (71/302; 24% p=0.002). Mutations in PIK3CA were
more common in MSI positive tumors (43/158; 27%) compared
to MSS tumors (61/306; 20%), although this was not significant
(p=0.08). Figure 2 summarizes the patterns of mutations and
association with MSI status.
Based on our understanding of receptor tyrosine kinase-MAPK
signaling, and our preliminary analysis of 115 endometrial tumors,
we anticipated that FGFR2 and KRAS mutations would occur in a
mutually exclusive pattern. Indeed, only 4/87 (5%) KRAS
mutation-positive tumors carried a FGFR2 mutation (S252W x2,
P253R, L398M), whereas 44/377 (12%) KRAS mutation negative
tumors carried an FGFR2 mutation (p=0.05, two-tailed Fisher’s
exact test). To investigate whether the tumors carrying mutations
in both FGFR2 and KRAS were polyclonal, DNA from a different
portion of the tumor was extracted from archived paraffin tissue
and in all four cases both mutations were confirmed.
Perhaps the most surprising finding from this cohort is that
mutations in KRAS and CTNNB1 demonstrated a similar pattern of
mutual exclusivity and rarely occurred together. In the 453 tumors
sequenced for both genes, 88 and 85 carried mutations in
CTNNB1 and KRAS, respectively. Of those tumors with CTNNB1
mutations, only 5/88 (5.7%) carried KRAS mutations, whereas 80/
365 (22%) of the CTNNB1-wildtype tumors carried a KRAS
mutation (p=0.0002, two-tailed Fisher’s exact test). Given
CTNNB1 mutations were significantly more common in MSS
tumors, we looked for the relationship between KRAS and
CTNNB1 mutations in both MSS and MSI tumors. This
association was even stronger in those tumors that demonstrated
microsatellite stability where 1/71 (1%) CTNNB1 mutation
positive tumors carried a KRAS mutation, whereas 44/230 (19%)
of the CTNNB1 wildtype tumors carried a KRAS mutation
(p=0.00004, two-tailed Fisher’s exact test). In contrast, this
association was not present in those tumors with MSI as 4/17
(24%) CTNNB1 mutation positive tumors carried an activating
KRAS mutation whereas 36/135 (27%) of the CTNNB1 wildtype
tumors carried a KRAS mutation.
Surprisingly, given the near mutual exclusivity of FGFR2 and
KRAS, and of CTNNB1 and KRAS, no such pattern was seen for
FGFR2 and CTNNB1. Specifically 8/88 (9%) CTNNB1 mutation
positive tumors carried an FGFR2 mutation, whereas 40/365
(11%) CTNNB1 wildtype tumors carried an FGFR2 mutation.
Within the MSS cohort of tumors, 7/71 (10%) CTNNB1 mutation
positive tumors carried an FGFR2 mutation whereas 17/230 (7%)
of the CTNNB1 wildtype tumors carried an FGFR2 mutation.
Association of mutations with clinicopathologic features
There was no association between FGFR2, KRAS, PIK3CA
mutation and age at diagnosis. CTNNB1 mutations were, however,
significantly more common in patients diagnosed before age 60
(49/183, 27%) compared to those diagnosed after age 60 (39/271,
14%) (p=0.0016, two-tailed Fisher’s exact test). We chose 60 as
our age cutoff based on previous data indicating reduced survival
in patients .60 [2]. There was no association between mutations
in any of the four oncogenes investigated and patient race. FGFR2
mutations were more common in Caucasian/Asian cases (46/411,
11%) than African American patients (2/55, 3%), albeit this was
not significant (p=0.10). PIK3CA mutations were significantly
more common in stage I/II tumors (93/384, 24%) compared to
late stage tumors (11/80, 13%) (p=0.04, two tailed Fisher’s exact
test) (Table S5). CTNNB1 mutations were significantly associated
with low tumor grade: grade 1, 59/243, (24%); grade 2, 25/149
(17%); grade 3, 4/62 (6%) (p=0.0027, two-tailed Fisher’s exact
Figure 1. Schematic figure of FGFR2 mutations identified in endometrioid endometrial tumors. Blue diamonds indicate each instance of
a mutation in the Washington University School of Medicine cohort. Mutations are numbered relative to FGFR2b (NP_075259.2). Mutations at 6
codons (S252, P253, Y376, C383, N550, K660) comprise .90% of all mutations identified.
doi:10.1371/journal.pone.0030801.g001
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with grade (grade 1, 29/249 (12%); grade 2 17/152 (11%); grade
3, 2/65 (3%) (p=0.10) (Table S6). As well and moderately
differentiated (grade 1,2) tumors have been shown to share a
similar genetic etiology, we also compared mutation frequency in
this group compared to high grade tumors. When analyzed in this
way, CTNNB1 mutations were significantly less common in high
grade tumors, 4/62 (6%) compared to lower grade tumors 84/
392, (21%) (p=0.004, two-tailed Fisher’s exact test) as were
FGFR2 mutations (grade 1/2, 46/401 (11%); grade 3, 2/65 (3%)
(p=0.04, two-tailed Fisher’s exact test).
Mutations, patient outcome and other clinicopathologic
features
Mutation status for the four oncogenes investigated was not
associated with overall survival (OS) in the total cohort of 466
cases. OS was associated with age .60 (p=0.0002), advanced
stage (III/IV) (p,0.0001), FIGO tumor grade 2 (p=0.0014),
FIGO grade 3, p,0.0001) and adjuvant therapy (p,0.0001)
(Table 2). Multivariate analysis did not indicate that the mutation
status of any gene was associated with OS but age .60 yrs,
advance stage and higher grade remained significantly associated
with shorter OS (Table 2, data not shown).
Figure 2. Pattern of KRAS, CTNNB1, FGFR2, PIK3CA mutations and MSI status in 466 endometrioid endometrial tumors. Gene mutations
and MSI positive status are depicted by colored bars. 258 tumors had a mutation in at least one of the genes evaluated, whereas 208 tumors did not
demonstrate mutation of KRAS, CTNNB1, FGFR2, or PIK3CA.
doi:10.1371/journal.pone.0030801.g002
Table 2. Hazard Ratio (HR) and 95% Confidence Interval (CI) for Cohort of 466 Endometrioid Endometrial Cancers.
Univariate Analyses
Disease Free Survival Overall Survival
HR Ratio 95% CI P HR Ratio 95% CI P
Age .60 1.47 0.88–2.45 0.14 2.01 1.39–2.92 0.0002
Race (Black) 1.36 0.70–2.66 0.37 1.39 0.88–2.19 0.16
FIGO stage IA/1B REF REF
FIGO stage IC 2.61 1.18–5.74 0.018 1.403 0.87–2.27 0.17
FIGO stage II 3.26 1.34–7.93 0.009 2.10 1.21–3.64 0.0083
FIGO stage III/IV 6.80 4.20–11.0 ,0.0001 3.79 2.65–5.42 ,0.0001
FIGO Grade 2 2.71 1.45–5.07 0.0019 1.85 1.27–2.70 0.0014
FIGO Grade 3 7.91 4.24–14.77 ,0.0001 4.34 2.85–6.60 ,0.0001
Adjuvant therapy 3.14 1.94–5.09 ,0.0001 2.02 1.46–2.81 ,0.0001
MSI 1.03 0.62–1.70 0.91 1.09 0.78–1.53 0.62
FGFR2 mutation 1.66 0.85–3.25 0.14 1.37 0.83–2.29 0.22
KRAS mutation 0.40 0.17–0.93 0.033 1.03 0.69–1.55 0.87
CTNNB1 mutation 0.58 0.28–1.22 0.15 0.70 0.44–1.11 0.13
PIK3CA mutation 0.74 0.40–1.38 0.34 0.71 0.47–1.08 0.11
Multivariate Analyses
Disease Free Survival* Overall Survival**
HR Ratio 95% CI P HR Ratio 95% CI P
FGFR2 1.83 0.90–3.73 0.097 1.34 0.79–2.27 0.28
KRAS 0.43 0.18–0.99 0.048 1.05 0.70–1.58 0.82
FGFR2
a 1.64 0.80–3.36 0.18 1.37 0.80–2.33 0.25
KRAS
b 0.45 0.19–1.06 0.067 1.08 0.71–1.63 0.73
*For DFS, the multivariate model included Stage 1C, II, III/IV, grade 2 and 3.
**For OS, the multivariate model included age, FIGO stage 1C, II, III/IV, grade 2 and grade 3.
aFGFR2 adjusted for KRAS in addition to covariates above.
bKRAS adjusted for FGFR2 in addition to covariates above.
doi:10.1371/journal.pone.0030801.t002
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disease free survival (DFS) (HR=0.40 95% CI 0.17–0.93;
p=0.03) whereas the mutation status of other genes was not
significantly associated with DFS. As expected, DFS was
associated with higher stage (III/IV) (p,0.0001), FIGO tumor
grade 2 (p=0.0019) and 3 (p,0.0001) and adjuvant therapy
(p,0.0001) in univariate analysis. Multivariate analysis showed
that the presence of a KRAS mutation remained significantly
associated with longer DFS (HR=0.43 95% CI 0.18–0.99;
p=0.048) (Table 2). When FGFR2 mutation status was incorpo-
rated into a multivariate analysis it showed a trend towards being
associated with shorter DFS (HR=1.83 95% CI 0.90–3.73;
p=0.097) although this finding was of marginal statistical
significance (Table 2). When both genes were included in a
multivariate model neither reached significance (Table 2).
CTNNB1 and PIK3CA mutations had no effect on the multivariate
model (data not shown). We did not include adjuvant therapy in
the multivariate model as analysis indicated it was not independent
of stage and grade.
Mutations in early-stage disease and association with
patient outcome
We then tested whether mutation status of any gene was
associated with outcome in patients with early stage disease,
defined as all stage I and II tumors. Univariate analysis revealed
shorter OS is associated with age (p=0.004), stage II (p=0.007)
and high tumor grade (FIGO grade 3) (p,0.0001) (Table 3). Both
FGFR2 mutation positivity and grade 2 differentiation showed a
trend towards shorter OS (HR=1.74; 95% CI 0.97–3.12;
p=0.065 and HR=1.52; 95% CI 0.98–2.33; p=0.059, respec-
tively). When FGFR2 mutation was analyzed taking into
consideration the effects of known prognostic factors variables, it
became more significantly associated with OS (HR=2.00 95% CI
1.09–3.65; p=0.025) (Table 3).
Univariate analysis revealed only high grade (p=0.0005); stage
II (p=0.009); adjuvant therapy (p=0.049) and the presence of an
FGFR2 mutation (p=0.019) were significantly associated with
shorter disease free survival (DFS) (Table 3). KRAS mutation
showed a trend towards associating with longer DFS (HR=0.26
95% CI 0.06–1.11 p=0.067) whereas CTNNB1 and PIK3CA
mutations were not associated with DFS. When each gene was
analyzed alone in multivariate analysis of early stage cancers,
FGFR2 mutation status remained a significant factor associated
with reduced DFS (HR=3.24; 95% CI 1.35–7.77; p=0.008)
(Table 3) and KRAS was significantly associated with longer DFS
(HR=0.23 CI 0.05–0.97 p=0.045). When both genes were
included in the model, FGFR2 remained significant (HR=3.03
CI 1.26–7.27 p=0.013). Kaplan-Meier survival plots showing the
Table 3. Hazard ratio (HR) and 95% confidence interval (CI) for cohort of 386 Stage I/II cases.
Univariate Analyses
Disease Free Survival Overall Survival
HR Ratio 95% CI P HR Ratio 95% CI P
Age .60 1.42 0.69–2.92 0.35 1.92 1.23–3.00 0.004
Race (Black) 1.27 0.49–3.30 0.62 1.35 0.79–2.30 0.27
FIGO stage IA/1B REF REF
FIGO stage IC 2.65 1.20–5.83 0.016 1.40 0.87–2.27 0.17
FIGO stage II 3.28 1.35–7.96 0.009 2.13 1.23–3.69 0.007
FIGO stage III/IV 1.56 0.70–3.50 0.27 1.52 0.98–2.33 0.059
FIGO Grade 2 4.49 1.92–10.50 0.0005 3.00 1.75–5.15 ,0.0001
FIGO Grade 3 2.07 1.01–4.28 0.049 1.47 0.95–2.29 0.087
Adjuvant therapy 1.17 0.58–2.38 0.66 1.17 0.78–1.76 0.44
MSI 2.72 1.18–6.28 0.019 1.74 0.97–3.12 0.065
FGFR2 mutation 0.26 0.06–1.11 0.069 1.39 0.89–2.17 0.15
KRAS mutation 0.92 0.38–2.23 0.85 0.82 0.48–1.38 0.45
CTNNB1 mutation 0.69 0.28–1.66 0.40 0.77 0.47–1.24 0.27
PIK3CA mutation 1.42 0.69–2.92 0.35 1.92 1.23–3.00 0.004
Multivariate Analyses
Disease Free Survival* Overall Survival**
HR Ratio 95% CI P HR Ratio 95% CI P
FGFR2 3.24 1.35–7.77 0.008 2.00 1.09–3.65 0.025
KRAS 0.23 0.05–0.97 0.045 1.29 0.81–2.03 0.28
FGFR2
a 3.03 1.26–7.27 0.013 2.05 1.12–3.75 0.021
KRAS
b 0.24 0.06–1.02 0.053 1.31 0.83–2.07 0.25
*For DFS, the multivariate model included Stage 1C, II, Grade 2 and 3.
**For OS, the multivariate model included age, FIGO Stage 1C, II, Grade 2 and Grade 3.
aFGFR2 adjusted for KRAS in addition to covariates above.
bKRAS adjusted for FGFR2 in addition to covariates above.
doi:10.1371/journal.pone.0030801.t003
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stage cancers are presented in Figure S1.
Discussion
Here we show the patterns of mutations in four endometrial
oncogenes in the largest cohort of endometrioid endometrial
tumors reported to date (n=466). Given the large number of
tumors in this single institution Washington University School of
Medicine cohort, novel insights have been revealed which have
not been evident with smaller subsets of tumors or in some cases
where disparate evidence had been reported in smaller panels of
tumors [27,28,29,30].
One finding that may have implications for understanding the
biology underlying endometrial cancer is the hereto-unrecog-
nized mutual exclusivity of CTNNB1 and KRAS mutations in this
cohort. Although 5 tumors were identified with mutations in both
genes the vast majority of tumors only carried mutations in either
KRAS or CTNNB1 (p=0.0002). This finding was not a reflection
of an association with MSI positive and negative tumors because
when we looked in only the MSS tumors, the association was
even more significant. Only 1% CTNNB1 mutation positive
tumors carried a KRAS mutation whereas 19% of the CTNNB1
wildtype tumors carried a KRAS mutation (p=0.00004, two-
tailed Fisher’s exact test). In most other cancers, mutual
exclusivity of gene activation is observed between two proteins
that map to the same signaling pathway, which makes intuitive
sense, as activation of the same pathway at two different nodes is
redundant. Although KRAS and CTNNB1 have very distinct roles
in the MAPK pathway and the Wnt/TCF signaling pathway
respectively, recent data suggests novel points of pathway
crosstalk in some cell types [31]. Additional work is needed to
identify the mechanistic basis and biological significance of the
mutual exclusivity of KRAS and CTNNB1 mutations in
endometrial cancer. We hypothesize the presence of unappreci-
ated crosstalk or a shared effector molecule between the two
pathways in endometrial cells. Alternatively, the caveat exists that
these two pathways do not demonstrate redundancy at the level
of a shared effector molecule but perhaps merely demonstrate
biological redundancy with regard to the functional effect
activation of either pathway has on the tumorigenic phenotype.
e.g. uncontrolled cellular proliferation.
In contrast to a previous study, our data suggest that mutations
in exon 20 of PIK3CA are not associated with poor prognosis [29].
Since finalizing these analyses, it has been reported that mutations
in exons 1–7 of PIK3CA are prevalent in endometrial cancer, and
comprise 50% of all mutations identified [32]. Restricting
mutation analysis to exons 9 and 20 is a limitation of the current
study, and it is possible that thorough mutational analyses may yet
reveal associations with clinicopathologic variables.
In this single institution series of endometrioid endometrial
cancers, the overall FGFR2 mutation rate was 10% (48/466). The
10% mutation rate for this large, unselected series is consistent
with the mutation rate reported by Dutt et al. (9/86, 10%) [33]
and Cheung et al. (24/243, 10%) [15]. In our initial report of
FGFR2 mutations in endometrial cancers we oversampled for cases
that had recurred and tumors with microsatellite instability [18],
which may explain in part the higher rate of mutations in that
selected population, given the association of FGFR2 mutation with
both defective DNA repair and recurrence in the current
unselected cohort.
A number of clinical and pathologic prognostic factors have
been evaluated in the search for markers to more accurately
predict risk of recurrence or death for patients with endometrial
carcinoma. Past studies have suggested tumor markers p53, p16,
estrogen receptor, progesterone receptor and HER2/neu may
have clinical utility in endometrial cancer for predicting lymph
node metastasis, prognosis and in directing treatment [34];
however, no molecular markers are routinely used clinically.
Tumor aneuploidy has also been assessed and may be of some
prognostic benefit for low grade cancers [35], however given its
requirement for fresh tissue, it is not always clinically practical. An
ongoing prospective multicenter study called Molecular Markers
in Treatment in Endometrial Cancer (MoMaTEC) is currently
accruing patients in Europe to investigate the predictive value of
p53, p16, estrogen receptor, progesterone receptor and HER2/
neu markers.
In this study we have identified that FGFR2 and KRAS have
prognostic significance within the cohort of endometrioid
endometrial cancers. Our data suggest that FGFR2 mutations
occur more often in the well and moderately differentiated
endometrioid tumors (G1, G2) compared to undifferentiated
tumors and possibly identify the ‘‘bad actors’’ in an otherwise
better prognosis histological subgroup. Recent data in an
independent cohort of endometrial tumors reported a similar
frequency of mutations across G1–G3 tumors [15]. This disparity
could be explained by the fact that in that cohort, the
pathogenicity of the identified mutations is uncertain as many
were novel and their somatic status was not confirmed. A poorly
differentiated histology was one of the strongest predictors of
recurrence and/or progression in both the overall cohort and in all
early stage cancers in both univariate and multivariate analyses,
consistent with previous reports [2,3,5,36]. Notably, the associa-
tion of FGFR2 with shorter DFS is more significant in the
multivariate analyses where the association of high grade with
poor prognosis is accounted for, compared to univariate analysis.
These findings strongly suggest that the observed effect of FGFR2
is not simply due to the confounding effects of other known
prognostic factors, and underscore the likely functional signifi-
cance of this gene in determining survival.
A novel finding of this present study is that KRAS mutation is
associated with longer DFS in the total cohort in both univariate
and multivariate analysis. In the subset of early stage cases, KRAS
mutation was significantly associated with longer DFS in
multivariate analysis after adjusting for grade and stage. We can
speculate that the pattern of mutual exclusivity of FGFR2 and
KRAS suggests that the role of these two genes in endometrial
cancer initiation is likely to be through activation of the MAPK
signaling pathway. The fact that they have different and indeed
opposing effects on disease free survival leads us to further
speculate that activation of ‘‘non-MAPK’’ pathways downstream
of FGFR2 is driving the association of this gene with poor
prognosis.
Our finding that FGFR2 mutation is an independent prognostic
marker in patients with early stage endometrioid endometrial
cancer suggests that FGFR2 mutation testing could ultimately
prove useful in the management of endometrial cancer. Current
National Comprehensive Cancer Network (NCCN) guidelines for
endometrioid endometrial cancer confined to the uterus recom-
mends more aggressive adjuvant therapy as tumor grade and
tumor stage increases, and also where multiple adverse prognostic
indicators are present, including lymphovascular space involve-
ment. We envisage that the mutation status of FGFR2 could be
used to inform clinical decision making in a similar way to a poorly
differentiated histology. Specifically, the presence of an FGFR2
mutation and absence of a KRAS mutation would stratify a
patient as having high-risk disease, resulting in a recommendation
for more aggressive therapy (See Figure 3).
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an important step in validating the potential clinical utility of
FGFR2 as a prognostic marker. The key limitations to our current
finding are 1) that the patient samples are from a single institution,
2) the frequency of recurrence in early stage endometrioid cases is
relatively low in this unselected cohort and 3) we had low number
of late stage G1 and G2 tumors in this cohort which may have
contributed to lack of statistical significance for FGFR2 in the
entire cohort. We are currently sequencing the four exons of
FGFR2 containing almost all reported mutations in endometrial
cancer samples collected as part of the multi-institutional GOG-
210 clinical trial ‘‘Molecular Staging of Endometrial Cancer’’.
This cohort also allows the assessment of FGFR2 mutations on
endometrial cancer specific survival as well as overall survival,
given the extensive clinical annotation of these samples.
Preclinical data suggests that FGFR2 mutation testing may
identify patients whose tumors will be sensitive to FGFR inhibition
[11,37]. A large number of FGFR inhibitors are in development,
preclinical studies, and clinical trials [38]. Currently, several multi-
target kinase inhibitors with activity against multiple kinases
including FGFRs are being evaluated in endometrial patients
with advance stage or recurrent endometrial cancer (Brivinib,
NCT00888173; E7080, NCT01111461, Dovitinib, NCT0
1379534) and additional trials with more specific FGFR inhibitors
are planned. The validation of FGFR2 mutations as an
independent prognostic marker in early stage tumors and the
eventual identification of an FGFR inhibitor with clinical activity
in patients with metastatic endometrial cancer, holds the promise
of utilizing anti-FGFR therapies in an adjuvant setting to reduce
the risk of recurrence in patients diagnosed with FGFR2 mutation
positive endometrial cancer.
In conclusion, our mutation analysis of four oncogenes
frequently mutated in the endometrioid histology of endometrial
cancer revealed that mutated FGFR2 was associated with shorter
disease free progression and this was significant in patients
diagnosed with early stage disease. This finding has clinical
significance in that FGFR2 mutation status could function as a
starting point in developing a molecular prognostic risk assessment
score that could be used to identify patients that may benefit from
more aggressive adjuvant radiation and/or chemotherapy follow-
ing an initial hysterectomy. In the longer term, anti-FGFR agents
could be tested in patients with FGFR2 mutation positive tumors to
evaluate whether these agents reduce the frequency of recurrence
in the adjuvant setting, in addition to the metastatic setting where
they are currently being evaluated. As KRAS mutations were
associated with reduced recurrence risk in this cohort, our data
would suggest that MEK inhibition may not be effective in an
adjuvant setting to prevent recurrence.
Supporting Information
Figure S1 Kaplan Meier curves for recurrence/progres-
sion free survival (A) and overall survival (B) by FGFR2
mutation status in patients with early stage endometrial
cancer.
(TIF)
Table S1 Clinicopathological features of endometrial
tumors with FGFR2 mutations.
aNumbering relative to
NM_022970.2
bNumbering relative to NP_075259.2
cThese
mutations have been reported previously (8).
(DOC)
Table S2 KRAS Mutations in Endometrial Tumors.
(DOC)
Table S3 PIK3CA Mutations in Endometrial Tumors.
#These mutations are novel and do not appear in Cosmic (May
2011).
(DOC)
Table S4 CTNNB1 Mutations in Endometrial Tumors.
(DOC)
Table S5 Frequency of MSI and mutations, according to
FIGO stage.
(DOC)
Figure 3. Potential utility of FGFR2 mutation status as an adverse prognostic factor to affect clinical decision-making. The decision
tree is adapted from 2011 National Comprehensive Cancer Network guidelines using FIGO 2009 staging. BT=brachytherapy; RT=radiation therapy.
doi:10.1371/journal.pone.0030801.g003
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